Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) a Bayesian Optimal Phase II study
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Avatrombopag (Primary)
- Indications Aplastic anaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms DIAAMOND-Ava FIRST
- 13 Dec 2022 Results (n=40) assessing safety and efficacy of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naive and Relapsed/Refractory Severe Aplastic Anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Nov 2019 Status changed from not yet recruiting to recruiting.
- 24 Jul 2019 New trial record